Health Equity Data Access Program (HEDAP)
Forecast
Center for Medicare and Medicaid Services plans to offer grants of up to $90,000 to nonprofits and colleges and universities. It expects to make about 6 awards. It is a forecast, and no dates have been set yet.
From the official notice on Grants.gov, last changed July 25, 2024. Checked October 31, 2026.
- Award ceiling$90,000
- Award floornot stated
- Expected awards6
- Total fundingnot stated
- Cost sharingNot required
- Funding typeGrant
Key dates
| Forecast posted | July 25, 2024 |
|---|
Who can apply
This opportunity is open to nonprofits and colleges and universities.
- Public and State controlled institutions of higher education
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
Is this a realistic fit?
- No cost sharing or match is required.
What the grant funds
The Health Equity Data Access program (HEDAP) provides funding for six (6) “seats” in the CMS Virtual Research Data Center (VRDC). The VRDC assists researchers in gaining access to CMS restricted data for minority health research. Seats, in this context are defined as an individual user with VRDC access. These researchers will conduct health services research on health care topics such as physical health, oral health, behavioral health, population health, and social determinants of health focusing on, but not limited to, racial and ethnic minority groups; people with disabilities; members of the lesbian, gay, bisexual, transgender, and queer (LGBTQ+) community; individuals with limited English proficiency; individuals residing in rural areas; and individuals (including children, youth, and families) adversely affected by persistent poverty or inequality. The HEDAP supports specific applied research projects that relate to creative and innovative methods utilizing CMS data to identify, document, assess, and evaluate health disparities among Medicare and Medicaid and CHIP enrollees. The project should enhance the capacity of the researcher to understand and utilize CMS data in future research projects. Additionally, HEDAP encourages cutting-edge proposals that explore intersectionality. “Intersectionality” means that people belong to more than one group and, therefore, may have overlapping health and social inequities, as well as overlapping strengths and assets. Results of the HEDAP will provide CMS and its partners, (e.g. Quality Improvement Organizations, Hospital Engagement Networks, and other stakeholders) with actionable information on the subgroups of enrollees. This will aid the efforts of CMS and its agents to identify and eradicate health disparities in underserved populations. VRDC seat access will be funded for a period of 36 months each, based on the availability of funds.
How to apply
- Read the full notice and attachments on Grants.gov. The notice is the official source for deadlines and requirements.
- Make sure your organization has an active SAM.gov registration and Unique Entity ID; registration can take several weeks.
- Register on Grants.gov and submit through Workspace before the deadline and time given in the notice. Our application guide walks through each step.
Questions go to HEResearch@cms.hhs.gov, HEResearch@cms.hhs.gov, HEResearch@cms.hhs.gov.
Questions people ask
Who can apply for Health Equity Data Access Program (HEDAP)?
Center for Medicare and Medicaid Services accepts applications from nonprofits and colleges and universities.
What is the deadline for Health Equity Data Access Program (HEDAP)?
Forecast, no dates yet. Confirm the date and time in the official notice on Grants.gov.
How much funding is available?
Awards of up to $90,000 each.
Similar open grants
- Continuation of the Collaborative Islet Transplantation Registry (U01 Clinical Trial Not allowed)
- BRAIN Initiative Cell Atlas Network (BICAN): Coordinating Unit for Biostatistics, Informatics, and Engagement (CUBIE)
- Centers without Walls for mechanisms of neurodegeneration in Alzheimer’s disease-related dementias (ADRD)
- Expanding the Therapeutic Pipeline for Treating and Preventing Alzheimer's Disease and Related Dementias: Preclinical Validation and Drug Discovery for Novel Candidate Targets (U01 Clinical Trial Not Allowed)
- Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE, RP1 Clinical Trial Not Allowed)
- Exposomic Contributions to ADRD Pathology and Resilience